Metformin Impairs Systemic Bile Acid Homeostasis Through Regulating SIRT1 Protein Levels.

Qi Chen,Xiaoying Yang,Huabing Zhang,Xingxing Kong,Lu Yao,Xiaona Cui,Yongkang Zou,Fude Fang,Jichun Yang,Yongsheng Chang
DOI: https://doi.org/10.1016/j.bbamcr.2016.10.020
IF: 5.011
2016-01-01
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Abstract:Metformin is widely used to treat hyperglycemia. However, metformin treatment may induce intrahepatic cholestasis and liver injury in a few patients with type II diabetes through an unknown mechanism. Here we show that metformin decreases SIRT1 protein levels in primary hepatocytes and liver. Both metformin-treated wild-type C57 mice and hepatic SIRT1-mutant mice had increased hepatic and serum bile acid levels. However, metformin failed to change systemic bile acid levels in hepatic SIRT1-mutant mice. Molecular mechanism study indicates that SIRT1 directly interacts with and deacetylates Foxa2 to inhibit its transcriptional activity on expression of genes involved in bile acids synthesis and transport. Hepatic SIRT1 mutation elevates Foxa2 acetylation levels, which promotes Foxa2 binding to and activating genes involved in bile acids metabolism, impairing hepatic and systemic bile acid homeostasis. Our data clearly suggest that hepatic SIRT1 mediates metformin effects on systemic bile acid metabolism and modulation of SIRT1 activity in liver may be an attractive approach for treatment of bile acid-related diseases such as cholestasis.
What problem does this paper attempt to address?